You Ni

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of You Ni

Quick Facts

Property Description
Active ingredient Meloxicam
Form Tablets, Oral Suspension, Capsules, Solution for Injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of inflammation, pain, and fever
Origin Synthetic compound (Enolic acid derivative)

The Identity and Classification of You Ni (Meloxicam)

You Ni is the trade name for the active pharmaceutical ingredient Meloxicam, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Descriptions confirm that Meloxicam belongs to the broad category of medicines used to manage inflammation and its associated discomfort. This medicine is a synthetic compound that functions as a core therapeutic agent in the systemic management of discomfort stemming from inflammation, pain, and fever. Meloxicam belongs specifically to the oxicam class of NSAIDs, chemically categorized as an enolic acid derivative.

Composition, Origin, and Available Forms

The formulation of You Ni is characterized by its use of Meloxicam as a single active ingredient product (monotherapy). The medicine is presented in multiple principal dosage form(s), including conventional tablets, an oral suspension, capsules, and a solution for injection. This allows for multiple routes of administration, primarily oral or parenteral (injection), incorporating standard pharmaceutical excipients necessary for reliable systemic delivery. Meloxicam is clinically recognized for its preferential inhibitor action against the COX-2 enzyme, a distinguishing characteristic within the NSAID group.

General Therapeutic Purpose and Action Profile

The general therapeutic purpose of You Ni is to mitigate physical discomfort by targeting the underlying processes that contribute to inflammation, pain, and stiffness. It achieves this by functioning as a preferential modulator of the inflammatory process, thus yielding potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) effects. The overall functional benefit is the reduction of general inflammatory load, leading to improved physical comfort and functional capacity, such as easing the stiffness often associated with various inflammatory joint conditions. This profile is consistent with the drug’s intended use in managing the symptoms of persistent pain and swelling.

Regulatory References

  1. MedlinePlus Drug Information on Meloxicam

What side effects are possible with You Ni?

Adverse Reaction Scope

Category Entity/Classification (Strictly from Regulatory Documents)
Key adverse reaction categories Gastrointestinal (GI) disorders, serious Cardiovascular (CV) thrombotic events, Hepatic effects, Renal disorders, Serious Skin Reactions.
Frequency classification Most Common (5%): Diarrhea, Upper Respiratory Tract Infections, Dyspepsia, Influenza-like symptoms. Common (1%-10%): Hypertension, Peripheral Edema, Nausea, Vomiting, Dizziness, Headache.
System-organ classes involved Gastrointestinal Disorders, Nervous System Disorders, Vascular and Cardiac Disorders, Renal and Urinary Disorders, Hepatobiliary Disorders, Skin and Subcutaneous Tissue Disorders, Blood and Lymphatic System Disorders.
Serious adverse reactions Serious Cardiovascular (CV) Thrombotic Events (including myocardial infarction and stroke). Serious Gastrointestinal (GI) Adverse Events (including bleeding, ulceration, and perforation). Serious Skin Reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis).
Population-specific safety considerations Geriatric Patients are documented as having a greater risk for serious GI, cardiac, and renal problems. Pregnancy is contraindicated from about 30 weeks gestation onward due to fetal risk. Renal Impairment has usage restrictions, including a contraindication in non-dialysed severe renal failure.
Dose- or exposure-related patterns Risk of serious CV thrombotic events may occur as early as the first weeks of treatment and increases with the duration of use. Serious GI adverse events can occur at any time during use and without warning symptoms.
Safety-related restrictions or limitations Contraindicated in the setting of perioperative pain management for Coronary Artery Bypass Graft (CABG) surgery. Contraindicated in patients with active or recurrent peptic ulcer/haemorrhage, severe heart failure, or severely impaired liver function (as defined in regulatory labeling).

Safety Classifications (High-Level)

Classification Type Regulatory Statement (Strictly Label-Based)
Regulatory frequency framework used Utilizes frequency classifications (e.g., Most Common, Common, Uncommon, Rare) consistent with regulatory reporting standards.
Regulatory basis Factual statements are derived from authoritative governmental and intergovernmental sources, including the FDA Prescribing Information and EMA Summary of Product Characteristics.
Context-of-use safety notes Concomitant use with aspirin is officially documented as increasing the risk of serious GI adverse events. Contraindication in individuals with a history of aspirin-sensitive asthma.

Resulting Safety Structure

Regulatory safety summary:

  • The official safety profile is anchored by specific warnings regarding the potential for serious cardiovascular thrombotic events and serious gastrointestinal adverse events (e.g., bleeding and perforation).
  • Adverse reactions are systematically documented by frequency and grouped into System-Organ Classes, with common effects often involving the gastrointestinal system (e.g., dyspepsia, diarrhea) and the nervous system (e.g., headache).
  • Specific safety restrictions apply to certain patient populations (e.g., older adults) and clinical situations (e.g., CABG surgery, severe organ impairment), which are formally listed as contraindications or major precautions in the label.
  • The risk of serious cardiovascular events is explicitly linked to duration of use, documented as increasing as early as the first weeks of treatment and continuing to rise with prolonged exposure.

Connection to the overall safety profile (2–4 sentences):

The official safety information structures the understanding of Meloxicam's risk profile by detailing both common, expected adverse reactions and defining the small potential for serious, life-threatening events in the cardiovascular and gastrointestinal systems. This regulatory documentation also clearly defines the patient populations and clinical circumstances where use is restricted or associated with higher risk, such as advanced pregnancy or severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for You Ni (Meloxicam) describes the documented clinical spectrum of overdose, outlining both common and life-threatening systemic outcomes. All overdose situations must be managed with symptomatic and supportive care.

Documented Overdose Manifestations

The most commonly reported clinical manifestations of acute overdose are typically limited to non-specific symptoms such as lethargy, drowsiness, nausea, vomiting, and epigastric pain. Severe exposure, however, can lead to serious systemic toxicity. Documented severe outcomes include Gastrointestinal Bleeding, Acute Renal Failure, Hepatic Dysfunction, Hypertension, Convulsions, Cardiovascular Collapse, and Cardiac Arrest.

Mandated Emergency Response

Regulators explicitly state the need for immediate emergency medical attention in cases of suspected overdose. Urgent medical help is required if a patient shows signs of a severe reaction, such as an anaphylactic reaction, or if collapse, seizure, or trouble breathing occurs. The FDA prescribes immediately calling emergency services under these conditions.

No specific antidote is known for Meloxicam overdose. Officially described supportive measures may include the use of gastric lavage and activated charcoal within specific timeframes. Furthermore, the official profile notes that procedures like hemodialysis are not expected to be useful due to the drug’s high protein binding.

Therapeutic Uses of You Ni

What You Ni Treats: Main Uses and Benefits

The medication is relevant for the symptomatic management of conditions characterized by episodic or fluctuating manifestations, such as chronic inflammatory joint diseases, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. It is applied across these conditions to address the pronounced symptoms of joint pain, swelling, and stiffness that often create noticeable interference with daily stability. The benefit provided helps ease the overall symptom burden and supports general well-being during symptomatic phases.

You Ni may assist with symptomatic management in clinical settings that involve acute or unstable symptom patterns, such as managing discomfort arising from skeletomuscular injuries or providing post-operative analgesia. This is relevant across domains involving significant symptom expression, including its application in certain Juvenile Idiopathic Arthritis (JIA) contexts for relevant patient groups.

“By easing challenging physical symptoms, the medication assists with maintaining functional stability during symptomatic periods.”


Quick Fact: Symptom Support

Symptom Category Symptom Focus Typical Contexts
Pain Musculoskeletal discomfort, tenderness Chronic arthritis, post-surgical pain
Inflammation Joint swelling, localized redness Flares of rheumatic diseases
Stiffness Functional capacity, limited mobility Post-rest symptoms, chronic joint diseases

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use You Ni (Meloxicam)

The eligibility for You Ni (Meloxicam) is strictly defined by government regulatory documents, focusing on patient age, reproductive status, and pre-existing medical conditions.


Eligibility Scope

Classification Population/Condition Restriction Basis
Contraindicated Patients with a history of NSAID or Aspirin hypersensitivity Absolute prohibition due to cross-reactivity risk.
Contraindicated Patients with active peptic ulceration or GI bleeding High risk of serious gastrointestinal events.
Contraindicated Women in the third trimester of pregnancy (after 30 weeks) Risk to the fetal cardiovascular system.
Contraindicated Patients with severe heart failure (NYHA Class III/IV) Risk of fluid retention and cardiac event exacerbation.
Contraindicated Pain management after CABG surgery Increased risk of myocardial infarction and stroke.
Allowed Adults (18 years and older) Approved for general indications.
Restricted Pediatric patients (2 to 16 years) Approved only for Juvenile Idiopathic Arthritis (JIA).
Restricted Patients with mild-to-moderate renal/hepatic impairment Requires careful monitoring of organ function.

Regulatory Basis for Eligibility

Regulatory documents define eligibility by establishing absolute contraindications for populations with severe pre-existing conditions or high surgical risk, such as those with active GI bleeding or those post-CABG surgery. Eligibility is also structured by age, with established use in children ge 2 years restricted only to the indication of Juvenile Idiopathic Arthritis. Use during the third trimester of pregnancy is strictly prohibited.

What should I know about interactions with other medicines?

The interaction profile for You Ni (Meloxicam) is defined by official constraints against combinations that increase the risk of bleeding and renal impairment.

Documented Pharmacodynamic Risks

Co-administration with other NSAIDs (Non-Steroidal Anti-inflammatory Drugs), including COX-2 selective inhibitors, is formally restricted and should be avoided due to the additive risk of gastrointestinal ulceration and bleeding. This heightened risk also applies to concurrent use with oral anticoagulants (e.g., Warfarin), antiplatelet agents, oral corticosteroids, and SSRIs (Selective Serotonin Reuptake Inhibitors).

Renal and Hemodynamic Interactions

Meloxicam may diminish the efficacy of Diuretics, ACE Inhibitors, and ARBs (Angiotensin Receptor Blockers). The official label notes that this co-administration may result in the deterioration of renal function, a risk particularly highlighted in the elderly, volume-depleted patients, or those with pre-existing renal impairment.

Clearance and Exposure Changes

Co-administration may result in increased plasma concentrations and potential toxicity of other drugs, notably Lithium and Methotrexate (when used at high doses). Meloxicam's metabolism involves CYP2C9 as the primary enzyme, and regulatory guidance addresses the resulting higher systemic exposure in individuals known to be poor metabolizers.

Substance and Food Constraints

Regulatory documents caution that consuming alcohol increases the risk of stomach bleeding. Additionally, a high-fat breakfast is officially documented to increase the maximum concentration (Cmax) of Meloxicam, although the total extent of absorption remains unaffected. No clinically significant pharmacokinetic interaction is noted with common antacids.

Mechanism of Action

Selective Modulation of the Cyclooxygenase-2 Enzyme

You Ni's action is fundamentally defined by its role as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, the inducible molecular target responsible for synthesizing pro-inflammatory prostaglandins. By occupying the active site of COX-2, the drug reduces the synthesis of these mediators at the site of inflammation, thereby influencing the biochemical processes of the inflammatory response.

Attenuation of Prostaglandin-Mediated Signaling

The resulting decrease in prostaglandin concentration (particularly PGE2) produces two primary physiological consequences. Peripherally, it reduces the sensitization of nociceptors (pain-sensing nerves), which alters the firing frequency within nociceptive pathways. Centrally, the mechanism influences the hypothalamus by diminishing PGE2 production, which allows for the downward resetting of the central temperature set point.

Mechanistic Boundaries and Constraints

The drug’s mechanism is strictly limited to the COX pathway; it does not modulate the parallel lipoxygenase pathway and therefore leaves leukotriene synthesis unaffected. Furthermore, although preferential, the mechanism involves residual inhibition of the constitutive COX-1 enzyme, which results in the alteration of physiological processes mediated by baseline prostaglandin activity.

Dosage and Administration Information

You Ni (Meloxicam) is administered via two primary routes: oral and intravenous (IV). The oral route encompasses several available forms, including tablets, capsules, and an oral suspension, though these formulations are generally considered non-interchangeable. The medicine is specifically taken once daily for all approved adult oral and intravenous regimens.

For adult oral use, the usual starting and maintenance dose is 7.5 mg, which may be adjusted up to a maximum daily limit of 15 mg. The intravenous form is reserved for specific pain management contexts and is administered as a single 30 mg IV bolus over a minimum of 15 seconds. The overall procedural rule guiding treatment duration is the application of the lowest effective dose for the shortest duration consistent with treatment goals.

The administration process includes specific instructions regarding intake conditions. Oral dosage forms may generally be taken with or without food, but if the oral suspension is used, the container must be gently shaken before measuring the dose. Dosage modifications are stipulated for specific populations to prevent procedural errors. For instance, the daily dose should not exceed 7.5 mg for patients with severe renal impairment who are on hemodialysis. Similarly, long-term use in older adults typically adheres to the lower daily dose of 7.5 mg. If an individual dose is missed, the instruction is to take it when remembered, but to avoid doubling the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for You Ni (Meloxicam)

The research foundation for You Ni is built upon the systemic evaluation of its role in the study of symptoms across various chronic inflammatory joint conditions. The available evidence base is composed mainly of Randomized Controlled Trials (RCTs) and supporting Systematic Reviews published in peer-reviewed scientific literature, with supplemental long-term information collected through observational studies. This research describes the monitoring of patient-reported outcomes related to perceived discomfort and changes in daily functioning or activity level.


Evidence for Use in Osteoarthritis and Rheumatoid Arthritis

The consistency and volume of controlled studies for the study of symptomatic conditions in adult populations with Osteoarthritis (OA) and Rheumatoid Arthritis (RA) contribute to the evidence base being widely characterized as High. For OA, research has explored the medicine in trials assessing short-term or episodic symptom patterns, primarily evaluating Pain Intensity and Joint Stiffness. For RA, studies conducted on adults evaluated outcomes related to changes in functional status, such as counting Tender and Swollen Joints. The existing evidence base, however, does not include research on altering the underlying course of the disease, as the studies are focused on symptomatic outcomes.


Evidence for Use in Ankylosing Spondylitis

The consistency and nature of the controlled trials for the study of symptomatic conditions in Ankylosing Spondylitis (AS) contribute to the evidence level being widely characterized as High. These trials focused on adults with symptomatic AS, evaluating outcomes related to symptom severity and functional capacity, including the duration of Morning Stiffness. Research provides context, describing group patterns related to these outcomes, and some studies continued to monitor responses over longer durations.


Evidence in Pediatric Populations (Juvenile Idiopathic Arthritis)

The evidence base for use in pediatric patients relates to Juvenile Idiopathic Arthritis (JIA). The research available consists primarily of Active-Controlled Trials that utilized the ACR Pediatric 30% Improvement Criteria to monitor change, comparing observed patterns against other active agents in the field. This evidence base is generally categorized as Moderate, reflecting the findings within controlled study settings for these specific subgroups.


What is Still Uncertain About the Research

Core assessments for monitoring acute symptoms are often completed within short-term follow-up durations (e.g., 4 to 12 weeks). While observational data exists for periods up to one year, research exploring the very long-term effects of this class of medicine is not fully established, and evidence for chronic outcomes beyond one year is limited. Furthermore, research highlights that generalizability to less-studied JIA subtypes may be limited.

Frequently Asked Questions (FAQ)

Common questions about You Ni (FAQ)


Q: Do you feel You Ni working right away?

Official information indicates that You Ni is primarily used for managing chronic inflammatory conditions and may have a delayed time to onset of its full effect. It is generally described as requiring time to reach its full steady state in the body. Because of this longer onset time, official prescribing information notes it is typically not intended for the management of patients requiring immediate relief from acute pain.


Q: How long does the effect of You Ni typically last?

Regulatory information confirms that You Ni has a relatively long half-life in the body, which describes how long it takes for the medicine's concentration to decrease by half. This long half-life is consistent with the medicine's usual administration frequency.


Q: Can You Ni interact with common pain relievers like ibuprofen?

Yes, official regulatory documents strongly advise against taking You Ni concurrently with aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including common ones like ibuprofen or naproxen. Official documents indicate that using these medicines together can increase the potential for serious adverse events, particularly concerning the gastrointestinal system, such as bleeding and ulceration.


Q: Can using You Ni make you feel dizzy or tired?

Yes, regulatory documentation lists dizziness as a common side effect of You Ni. Additionally, somnolence (drowsiness) and a general feeling of fatigue have been reported in the medicine's adverse reactions profile.


Q: Does You Ni affect hormone levels?

You Ni is a COX-2 inhibitor, but some official reports suggest that its use may cause a reversible delay in ovulation and can potentially cause trouble getting pregnant. These effects are related to how the medicine works in the body.


Q: Can You Ni be used by teenagers?

Use of You Ni in individuals under 18 years old is generally restricted, as confirmed by regulatory guidance. However, the medicine has been specifically studied and found to be effective for treating Juvenile Idiopathic Arthritis (JIA) in children aged 2 years and older. For all other approved adult conditions, regulatory documents indicate that use is not established for individuals under 18.


Q: Can You Ni be crushed or split?

The official product information for some tablet forms may include a score line, but this mark is not always intended for breaking the tablet into equal parts. Any alteration of solid dosage forms should be based on the specific instructions provided in the official patient information or by the manufacturer.


Q: Is You Ni available without a prescription?

Across most international markets, You Ni, in its standard strengths and formulations, is classified by regulatory authorities as a prescription-only medicine.


Q: Is it true that You Ni is being studied for other conditions?

While the primary approved uses are for inflammatory joint conditions, regulatory-reviewed information confirms that other fixed-dose combinations of the active ingredient are available and studied for other uses. These uses include the study of certain types of migraine headaches and for postsurgical pain management.


Q: Can You Ni cause problems with sleep?

Although 'sleep problems' are not listed as a common side effect, the official adverse event profile includes reports of somnolence (drowsiness). Because this is a central nervous system effect, it may indirectly influence a patient's normal sleep-wake cycle.


Q: Is You Ni safe to use if I have kidney issues?

Using You Ni requires caution if kidney issues are present. According to regulatory documents, patients with mild to moderate renal impairment typically do not need a dose reduction. However, the medicine is contraindicated (prohibited) in patients with severe renal impairment who are not undergoing dialysis.


Q: Why is You Ni sometimes prescribed for a short time only?

Regulatory guidance emphasizes the principle of using the lowest effective dose for the shortest duration necessary to control symptoms. This approach is consistent with the regulatory principle of using the lowest effective dose for the shortest duration necessary to control symptoms, as a measure to reduce potential undesirable effects. Short-term use is typically cited for the treatment of acute flare-ups of conditions like osteoarthritis.


Q: What should I do if I have a severe reaction to You Ni?

Official patient information advises that if signs of a severe allergic reaction or other serious adverse event occur, immediate emergency assistance should be sought. Such events include swelling of the face or throat, hives, or a severe skin rash.


Q: Is it normal to feel a mild stomach upset after taking You Ni?

Yes, according to official regulatory documentation, Dyspepsia is listed as one of the most common adverse reactions, meaning it occurs frequently in patients. Dyspepsia is a medical term that describes indigestion or upper abdominal discomfort, which a user might recognize as a 'mild stomach upset.'


Q: Has You Ni been approved in countries outside the US?

Yes, You Ni is a widely available medicine. The medicine has received regulatory authorizations from major international bodies, including the European Medicines Agency (EMA) for use across the European Union, and the Therapeutic Goods Administration (TGA) in Australia.


Q: Is You Ni known to cause any long-term health issues?

Official warnings highlight that the risk of serious cardiovascular thrombotic events (which include heart attack and stroke) and serious gastrointestinal adverse events (such as bleeding and perforation) may increase with the duration of use. These risks are explicitly linked to prolonged exposure.


Q: Are there restrictions on driving while using You Ni?

Official documents caution that side effects such as dizziness, somnolence (drowsiness), and other nervous system disorders have been reported. Because these effects can potentially impair reaction time and judgment, caution is advised when performing tasks that require concentration, like driving or operating machinery.


Q: Does You Ni have a risk of dependence or withdrawal symptoms?

No. You Ni is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Regulatory documents confirm that it is not classified as an opioid or a controlled substance and therefore has no documented risk of causing dependence or withdrawal symptoms.


Q: Can I stop using You Ni once I feel better?

Regulatory documents indicate that the need for symptomatic relief and the response to therapy should be re-evaluated periodically. Any decision regarding the continuation or discontinuation of use should be part of a therapeutic reassessment of the ongoing treatment goals.


Q: Is the active ingredient in You Ni naturally occurring?

No. The active ingredient, Meloxicam, is not naturally occurring. It is classified as a synthetic compound (a man-made chemical structure) that belongs to the oxicam class of NSAIDs.


Q: What patient groups were included in the main clinical trials for You Ni?

The official research base supporting the medicine's use included controlled studies in adults with Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). Separate studies were also conducted on pediatric patients for the indication of Juvenile Idiopathic Arthritis (JIA).


Q: What kind of warnings are included on the You Ni packaging?

Official labeling, including the highest-level warnings (often known as a Black Box Warning), emphasizes the potential for serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation).


Q: Are there any known common user mistakes when using You Ni?

Patient education materials highlight key administration points to avoid common mistakes. These include the warning to never double the dose to make up for a missed one, and the caution that different formulations (like tablets and suspensions) are not always interchangeable.


Q: Why is my doctor asking about my full medical history before prescribing You Ni?

Official documentation identifies many conditions and past medical events that represent significant risk. Since You Ni is contraindicated in patients with a history of serious events (e.g., GI bleeding, CABG surgery) or conditions requiring caution (e.g., severe heart failure, kidney impairment), a full medical history is essential for safe risk assessment.


Q: Is You Ni intended for lifelong use?

While You Ni is approved for use in chronic conditions, official regulatory guidance requires that the need for symptomatic relief and therapeutic response be re-evaluated periodically. Treatment is guided by the principle of using the shortest effective duration to control symptoms, rather than an automatic intent for lifelong use.


Q: What if I'm allergic to one of the inactive ingredients in You Ni?

Official documents strictly contraindicate the use of You Ni in patients with a known hypersensitivity (e.g., an allergic reaction) not just to the active ingredient, but also to any components of the drug product. This includes any inactive ingredients (excipients) used in the formulation.


Q: Does You Ni make your skin more sensitive to the sun?

The official adverse reaction profile includes reports of photosensitivity (increased sensitivity to sunlight) and other skin conditions. Some regulatory reviews have also mentioned the potential for this class of medicine to cause phototoxic reactions.

How should You Ni be stored and disposed of?

How to Store and Dispose of You Ni

Storage Requirements

You Ni must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). Brief temperature excursions are allowed from 15°C to 30°C (59°F to 86°F). To maintain product stability, the medicine must be protected from excessive moisture, light, and freezing.

The container, especially the oral suspension, must be kept tightly closed. As a mandatory safety requirement, the product must be stored strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired You Ni should not be flushed down the toilet or poured down a drain, as it is not on the official government flush list. The preferred disposal method is using an authorized drug take-back program or mail-back service.

If a take-back option is unavailable, the alternative procedure is to mix the medication with an undesirable substance, such as coffee grounds or cat litter, place the mixture in a sealed bag or container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of You Ni found in:

A-Z Index: